Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Michelle Purdom"'
Autor:
Lindsey E. Roeker, Tatyana A. Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey, Andrew D. Zelenetz, Lorenzo Falchi, Jae H. Park, David J. Straus, Camila Pena Velasquez, Sonia Lebowitz, Yehudit Fox, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Teja Turpuseema, Michelle Purdom, Dana Paskalis, Hari P. Miskin, Peter Sportelli, Lori A. Leslie, Anthony R. Mato
Publikováno v:
Clinical Cancer Research. 28:3958-3964
Purpose: Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an “add on” approach for patients who had been treated with ibrutinib in the
Autor:
Anthony R. Mato, Lori A. Leslie, Peter Sportelli, Hari P. Miskin, Dana Paskalis, Michelle Purdom, Teja Turpuseema, Rosalba Martignetti, Sabrina Kdiry, Elizabeth McCarthy, Meghan C. Thompson, Carissa Laudati, Kristen Battiato, Yehudit Fox, Sonia Lebowitz, Camila Pena Velasquez, David J. Straus, Jae H. Park, Lorenzo Falchi, Andrew D. Zelenetz, Colleen Dorsey, Gail Panton, Victoria Falco, Jacob D. Soumerai, Tatyana A. Feldman, Lindsey E. Roeker
Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48c05b3ff2d51e9213b86e98036b3c6f
https://doi.org/10.1158/1078-0432.22487868
https://doi.org/10.1158/1078-0432.22487868
Autor:
Anthony R. Mato, Lori A. Leslie, Peter Sportelli, Hari P. Miskin, Dana Paskalis, Michelle Purdom, Teja Turpuseema, Rosalba Martignetti, Sabrina Kdiry, Elizabeth McCarthy, Meghan C. Thompson, Carissa Laudati, Kristen Battiato, Yehudit Fox, Sonia Lebowitz, Camila Pena Velasquez, David J. Straus, Jae H. Park, Lorenzo Falchi, Andrew D. Zelenetz, Colleen Dorsey, Gail Panton, Victoria Falco, Jacob D. Soumerai, Tatyana A. Feldman, Lindsey E. Roeker
Purpose:Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an “add on” approach for patients who had been treated with ibrutinib in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a26e24bc38e973d8f286db775058e90
https://doi.org/10.1158/1078-0432.c.6532596
https://doi.org/10.1158/1078-0432.c.6532596
Autor:
Carolynn T Jones, Catherine A Griffith, Cheryl A Fisher, Kathleen A Grinke, Rosemary Keller, Hyacinth Lee, Michelle Purdom, Elyce Turba
Publikováno v:
J Res Nurs
Background Clinical Research Nurses practice across a wide spectrum of roles and settings within the global research enterprise. Clinical Research Nurses working with clinical trials face a dual fidelity in their role, balancing integrity of the prot
Autor:
Mazyar Shadman, Kaitlin Kennard, Daniel J. Landsburg, Peter Sportelli, Michelle Purdom, Danielle M. Brander, Anthony R. Mato, Pamela S. Becker, Patricia Y. Tsao, Eline T. Luning Prak, Hari P. Miskin, Lindsey E. Roeker, Dana Paskalis, Andrew D. Zelenetz, Beth Morrigan, Colleen Dorsey, Cara M King, Stephen J. Schuster, Michael S. Weiss, Sunita D. Nasta, Jakub Svoboda
Publikováno v:
Blood. 132:297-297
Introduction: Preclinical data suggest that PD-1 and PD-L1/PD-L2 mediate immune evasion in CLL. However, clinical data (Ding, BLOOD 2017) demonstrate that pembrolizumab monotherapy (pembro) is ineffective in relapsed/refractory (r/r) CLL patients (pt
Autor:
Anthony Polverino, Chaan Ng, Marilyn Mulay, Michael Bass, Robert S. Benjamin, Razelle Kurzrock, Roy S. Herbst, Andy Van Vugt, Michelle Purdom, Antonis Koutsoukos, Jeffrey M. Silverman, Lee S. Rosen, Jeffrey S. Wiezorek, Ren Y. Xu, David D. Chang, Yu Nien Sun
Publikováno v:
Journal of Clinical Oncology. 25:2369-2376
Purpose AMG 706 is an investigational, orally bioavailable inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and stem-cell factor receptor. This phase I, dose-finding study evaluated the s
Publikováno v:
Seminars in Oncology Nursing. 18:11-19
Objectives: To update the success and obstacles using therapies targeted to the epidermal growth factor receptor including IMC-C225, ZD1839, and OSI-774. Data Sources: Research articles, textbooks, clinical protocols, case studies. Conclusions: Ongoi
Autor:
Nathan Fowler, William G. Wierda, Michael S. Weiss, Peter Sportelli, Michelle Purdom, Matthew A. Lunning, Hari P. Miskin, Jonathon B. Cohen, Tanya Siddiqi, Marshall T. Schreeder, Jan A. Burger, Susan O'Brien, Loretta J. Nastoupil, Christopher R. Flowers, Julie M. Vose
Publikováno v:
Journal of Clinical Oncology. 35:7511-7511
7511 Background: Novel targeted agents are emerging for B-cell malignancies, but few studies have safely combined these agents. Ublituximab (UTX) is a novel glycoengineered mAb targeting a unique epitope on the CD20 antigen. TGR-1202 is a next genera
Autor:
Michelle, Purdom, Aki, Ohinata
Publikováno v:
Oncology (Williston Park, N.Y.). 21(11 Suppl 5)
All nursing personnel actively participate in the nursing process, with the registered nurse taking primary responsibility. Five steps in the nursing process include assessment, diagnosis, planning, implementation, and evaluation. Health-care profess
Autor:
Michelle, Purdom
Publikováno v:
Clinical journal of oncology nursing. 8(3)